ReviewLiver international : official journal of the International Association for the Study of the Liver2022
Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
Review in Liver international : official journal of the International Association for the Study of the Liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers.Clinical drug investigation · 2023Trial
- Albumin in the Management of Hepatorenal Syndrome-Acute Kidney Injury: Is There Ever Too Much?Digestive diseases and sciences · 2026Article
- Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).Pediatric nephrology (Berlin, Germany) · 2026Review
- United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.Hepatology (Baltimore, Md.) · 2025Review
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- Acute Kidney Injury in Cirrhosis Revisited-Implications in Clinical Practice.Gastro hep advances · 2025Article
- Terlipressin-Induced Skin Necrosis of 3 Cases: Should We Concern?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.Journal of hepatology · 2024Review
- Sound waves and solutions: Point-of-care ultrasonography for acute kidney injury in cirrhosis.World journal of critical care medicine · 2024Review
- Controversies Surrounding Albumin Use in Sepsis: Lessons from Cirrhosis.International journal of molecular sciences · 2023Review
- Formulary Drug Reviews: Terlipressin.Hospital pharmacy · 2023Review
- Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.Journal of hepatology · 2023Article
- Synthesis and clinical application of new drugs approved by FDA in 2022.Molecular biomedicine · 2023Review
- Use of albumin infusion for cirrhosis-related complications: An international position statement.JHEP reports : innovation in hepatology · 2023Article
- Acute Kidney Injury in Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2023Review
- Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial.Critical care explorations · 2023Article
- A hospitalist's approach to managing acute kidney injury (hepatorenal syndrome) in cirrhosis.Clinical liver diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
Abstract
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication of severe liver disease with a clinically poor prognosis. Supportive care using vasoconstrictors and intravenous albumin are the current mainstays of therapy. Terlipressin is an efficacious vasoconstrictor that has been used for 2 decades as the first-line treatment for HRS-AKI in Europe and has demonstrated greater efficacy in improving renal function compared to placebo and other vasoconstrictors. One of the challenges associated with terlipressin use is monitoring and mitigating serious adverse events, specifically adverse respiratory events, which were noted in a subset of patients in the recently published CONFIRM trial, the largest randomized trial examining terlipressin use for HRS-AKI. In this article, we review terlipressin's pharmacology, hypothesize how its mechanism contributes to the risk of respiratory compromise and propose strategies that will decrease the frequency of these events by rationally selecting patients at lower risk for these events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.